Nanoscale delivery systems for multiple drug combinations in cancer

Future Oncology

Volumn 7, Issue 11, 2011, Pages 1347-1357

  Cao, Yang ^a   Wang, Bochu ^a   Lou, Deshuai ^a   Wang, Yazhou ^a   Hao, Shilei ^a   Zhang, Lin ^a  

^a CHONGQING UNIVERSITY   (China)

Author keywords

combination therapy; delivery systems; multiple drugs; nanotechnology; tumor

Indexed keywords

AMINOGLUTETHIMIDE; BEVACIZUMAB; CAMPTOTHECIN; CISPLATIN; COMBRETASTATIN A4; CPX 351; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; FLOXURIDINE; FLUOROURACIL; GEMCITABINE; GONADORELIN; INTERLEUKIN 12; IRINOTECAN; MACROGOL; MITOMYCIN C; N (2 HYDROXYPROPYL)METHACRYLAMIDE; PACLITAXEL; UNCLASSIFIED DRUG; VINCRISTINE; WORTMANNIN;

ANGIOGENESIS; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER THERAPY; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG RELEASE; GROWTH INHIBITION; HUMAN; NANOANALYSIS; NANOFABRICATION; NONHUMAN; PRIORITY JOURNAL; REVIEW; TREATMENT FAILURE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; TISSUE DISTRIBUTION; TUMOR MICROENVIRONMENT;

EID: 80455126018     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.109     Document Type: Review

References (68)

1. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 303(5665), 1818-1822 (2004). (Pubitemid 38374867)
2. Davis ME, Chen Z, Shin DM. Nanoparticle therapeutics. an emerging treatment modality for cancer. Nat. Rev. Drug Discov. 7(9), 771-782 (2008).
3. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. Clin. Pharmacol. Ther. 83(5), 761-769 (2008). (Pubitemid 351556021)
4. Park J, Fong PM, Lu J et al. PEGylated PLGA nanoparticles for the improved delivery of doxorubicin. Nanomedicine 5(4), 410-418 (2009).
5. Phillips MA, Gran ML, Peppas NA. Targeted nanodelivery of drugs and diagnostics. Nano Today 5(2), 143-159 (2010).
6. Hobbs SK, Monsky WL, Yuan F et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc. Natl Acad. Sci. USA 95, 4607-4612 (1998). (Pubitemid 28207960)
7. Zhang H, Wang G, Yang H. Drug delivery systems for differential release in combination therapy. Expert Opin Drug Deliv. 8(2), 171-190 (2011).
8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646-674 (2011).
9. Greco F, Vicent MJ. Combination therapy. Opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Adv. Drug Deliver. Rev. 61(13), 1203-1213 (2009).
10. Lammers T, Subr V, Ulbrich K et al. Polymeric nanomedicines for image-guided drug delivery and tumor-targeted combination therapy. Nano Today 5(3), 197-212 (2010).
11. Logman JF, Heeg BM, Botteman MF, Kaura S, van Hout BA. Economic evaluation of zoledronic acid for the prevention of fractures in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the United Kingdom. Ann. Oncol. 21(7), 1529-1536 (2010).
12. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. Nat. Rev. Clin. Oncol. 7(11), 653-664 (2010).
13. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74, 47-61 (2001). (Pubitemid 32727608)
14. Chauhan VP, Lanning RM, Diop Frimpong B et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys. J. 97(1), 330-336 (2009).
15. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307(5706), 58-62 (2005). (Pubitemid 40093472)
16. Wang Y, Yang T, Wang X et al. Materializing sequential killing of tumor vasculature and tumor cells via targeted polymeric micelle system. J. Control. Release 149(3), 299-306 (2011).
17. Wang Z, Ho PC. A nanocapsular combinatorial sequential drug delivery system for antiangiogenesis and anticancer activities. Biomaterials 31(27), 7115-7123 (2010).
18. Sengupta S, Eavarone D, Capila I et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 436(7050), 568-572 (2005). (Pubitemid 41112931)
19. Jabr-Milane LS, van Vlerken LE, Yadav S, Amiji MM. Multi-functional nanocarriers to overcome tumor drug resistance. Cancer Treat. Rev. 34(7), 592-602 (2008).
20. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nature Rev. 2(1), 48-58 (2002). (Pubitemid 37328807)
21. Gillet JP, Efferth T, Remacle J. Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim. Biophys. Acta 1775(2), 237-262 (2007). (Pubitemid 46899341)
22. Wang JC, Goh BC, Lu WL et al. In vitro cytotoxicity of Stealth liposomes co-encapsulating doxorubicin and verapamil on doxorubicin-resistant tumor cells. Biol. Pharm. Bull. 28, 822-828 (2005).
23. Wu J, Lu YH, Lee A et al. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil. J. Pharm. Pharm. Sci. 10, 350-357 (2007). (Pubitemid 350065179)
24. Patil Y, Sadhukha T, Ma L, Panyam J. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance. J. Control. Release 136, 21-29 (2009).
25. Song XR, Zhao Y, Wu WB et al. PLGA nanoparticles simultaneously loaded with vincristine sulfate and verapamil hydrochloride. Systematic study of particle size and drug entrapment efficiency. Int. J. Pharm. 350, 320-329 (2008). (Pubitemid 351146679)
26. Song X, Zhao Y, Hou S et al. Dual agents loaded PLGA nanoparticles: systematic study of particle size and drug entrapment efficiency. Eur. J. Pharm. Biopharm. 69, 445-453 (2008).
27. Song XR, Cai Z, Zheng Y et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur. J. Pharm. Sci. 37, 300-305 (2009).
28. Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G. Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up. Acta Obstet. Gynecol. Scand. 87(12) 1343-1352 (2008).
29. Chen FM, Zhang M, Wu ZF. Toward delivery of multiple growth factors in tissue engineering. Biomaterials 31(24), 6279-6308 (2010).
30. Lammers T, Subr V, Ulbrich K et al. Simultaneous delivery of doxorubicin and gemcitabine to tumors in vivo using prototypic polymeric drug carriers. Biomaterials 30(20), 3466-3475 (2009).
31. Bae Y, Diezi TA, Zhao A, Kwon GS. Mixed polymeric micelles for combination cancer chemotherapy through the concurrent delivery of multiple chemotherapeutic agents. J. Control. Release 122(3), 324-330 (2007). (Pubitemid 47404677)
32. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A 4 and doxorubicin for tumor therapy. in vitro and in vivo studies. Eur. J. Pharm. Biopharm. 74, 467-473 (2010).
33. Cheng J, Teply BA, Sherifi I et al. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28(5), 869-876 (2007). (Pubitemid 44667020)
34. Vicent MJ, Greco F, Nicholson RI, Paul A, Griffiths PC, Duncan R. Polymer therapeutics designed for a combination therapy of hormone-dependent cancer. Angew. Chem. Int. Ed. Engl. 44, 4061-4066 (2005). (Pubitemid 40886448)
35. Greco F, Vicent MJ, Gee S et al. Investigating the mechanism of enhanced cytotoxicity of HPMA copolymer-DOX-AGM in breast cancer cells. J. Control. Release 117(1), 28-39 (2007). (Pubitemid 46164864)
36. Miller K, Erez R, Segal E, Shabat D, Satchi-Fainaro R. Targeting bone metastases with a bispecific anticancer and antiangiogenic polymer-alendronate- taxane conjugate. Angew. Chem. Int. Ed. Engl. 48, 2949-2954 (2009).
37. Krakovicova H, Etrych T, Ulbrich K. HPMA-based polymer conjugates with drug combination. Eur. J. Pharm. Sci. 37, 405-412 (2009).
38. Bagalkot V, Lee IH, Yu MK et al. A combined chemoimmunotherapy approach using a plasmid-doxorubicin complex. Mol. Pharm. 6, 1019-1028 (2009).
39. Chandna P, Saad M, Wang Y et al. Targeted proapoptotic anticancer drug delivery system. Mol. Pharm. 4, 668-678 (2007). (Pubitemid 350004266)
40. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. Adv. Drug Deliv. Rev. 60(15), 1615-1626 (2008).
41. Tran VT, Benoit JP, Venier-Julienne MC. Why and how to prepare biodegradable, monodispersed, polymeric microparticles in the field of pharmacy? Int. J. Pharm. 407, 1-11 (2011).
42. Shin HC, Alani AWG, Rao DA, Rockich NC, Kwon GS. Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs. J. Control. Release 140, 294-300 (2009).
43. Razem D, Katusin-Razem B. The effects of irradiation on controlled drug delivery/controlled drug release systems. Radiat. Phys. Chem. 77(3), 288-344 (2008). (Pubitemid 350297979)
44. Wang Y, Gao S, Ye WH, Yoon HS, Yang YY. Co-delivery of drugs and DNA from cationic core-shell nanoparticles self-assembled from a biodegradable copolymer. Nat. Mater. 5, 791-796 (2006). (Pubitemid 44570860)
45. Lee A, Wang Y, Cheng H, Pervaiz S, Yang YY. The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30, 919-927 (2009).
46. Aryal S, Hu C-MJ, Zhang L. Combinatorial drug conjugation enables nanoparticle dual-drug delivery. Small 6, 1442-1448 (2010).
47. Abraham SA, McKenzie C, Masin D et al. In vitro and in vivo characterization of doxorubicin and vincristine coencapsulated within liposomes through use of transition metal ion complexation and pH gradient loading. Clin. Cancer Res. 10, 728-738 (2004). (Pubitemid 38174011)
48. Tardi PG, Gallagher RC, Johnstone S et al. Coencapsulation of irinotecan and floxuridine into low cholesterol-containing liposomes that coordinate drug release in vivo. Biochim. Biophys. Acta 1768, 678-687 (2007). (Pubitemid 46275599)
49. Shuhendler AJ, Cheung RY, Manias J, Connor A, Rauth AM, Wu XY. A novel doxorubicin-mitomycin C co-encapsulated nanoparticle formulation exhibits anti-cancer synergy in multidrug resistant human breast cancer cells. Breast Cancer Res. Treat. 119, 255-269 (2009).
50. Ruenraroengsak P, Cook JM, Florence AT. Nanosystem drug targeting: facing up to complex realities. J. Control. Release 141(3), 265-276 (2010).
51. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9(8), 615-627 (2010).
52. Vasita R, Katti DS. Growth factor-delivery systems for tissue engineering. materials perspective. Expert Rev. Med. Devices 3(1), 29-47 (2006).
53. Balasubramanian V, Onaca O, Enea R, Hughes DW, Palivan CG. Protein delivery: from conventional drug delivery carriers to polymeric nanoreactors. Expert Opin Drug Deliv. 7(1), 63-78 (2010).
54. Chen FM, Shelton RM, Jin Y, Chapple IL. Localized delivery of growth factors for periodontal tissue regeneration: role, strategies, and perspectives. Med. Res. Rev. 29(3), 472-513 (2009).
55. Wan A, Sun Y, Gao L, Li H. Preparation of aspirin and probucol in combination loaded chitosan nanoparticles and in vitro release study. Carbohydr. Polym. 75, 566-574 (2009).
56. Kostarelos K, Bianco A, Prato M. Promises, facts and challenges for carbon nanotubes in imaging and therapeutics. Nat. Nanotechnol. 4(10), 627-633 (2009).
57. Chen AM, Zhang M, Wei D et al. Co-delivery of doxorubicin and Bcl 2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5, 2673-2677 (2009).
58. MacDiarmid JA, Mugridge NB, Weiss JC et al. Bacterially derived 400 nm particles for encapsulation and cancer cell targeting of chemotherapeutics. Cancer Cell 11(5), 431-445 (2007). (Pubitemid 46670079)
59. Lammers T. Improving the efficacy of combined modality anticancer therapy using HPMA copolymer-based nanomedicine formulations. Adv. Drug Deliv. Rev. 62(2), 203-230 (2009).
60. Verschraegen CF, Skubitz K, Daud A et al. A Phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 63(5), 903-910 (2009).
61. Kim HP, Gerhard B, Harasym TO et al. Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells. Exp. Hematol. 39, 741-750 (2011).
62. Feldman EJ, Lancet JE, Kolitz JE et al. First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute leukemia. J. Clin. Oncol. 29, 979-985 (2011).
63. Dicko A, Mayer LD, Tardi PG. Use of nanoscale delivery systems to maintain synergistic drug ratios in vivo. Expert Opin. Drug Deliv. 12(7), 1329-1341 (2010).
64. Chiu GNC, Wong MY, Ling LU et al. Lipid-based nanoparticulate systems for the delivery of anti-cancer drug cocktails: implications on pharmacokinetics and drug toxicities. Curr. Drug Metab. 10(8), 861-874(2009).
65. Zucker D, Barenholz Y. Optimization of vincristine-topotecan combination - paving the way for improved chemotherapy regimens by nanoliposomes. J. Control. Release 146(3), 326-333 (2010).
66. Mulder WJM, Strijkers GJ, van Tilborg GA et al. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res. 42 (7), 904-914 (2009).
67. Chen RR, Silva EA, Yuen WW et al. Spatio-temporal VEGF and PDGF delivery patterns blood vessel formation and maturation. Pharm. Res. 24(2), 258-264 (2007). (Pubitemid 46072185)
68. Wendel HG, De Stanchina E, Fridman JS et al. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 482(6980), 332-337 (2004). (Pubitemid 38418805)